Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Feb;59(2):283-285.
doi: 10.1007/s40262-019-00852-3.

Authors' Reply to Yu et al.: "Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?"

Didier Concordet  1 , Peggy Gandia  1 , Jean-Louis Montastruc  2 , Alain Bousquet-Mélou  1 , Peter Lees  3 , Aude A Ferran  1 , Pierre-Louis Toutain  4   5
Affiliations
Comment

Authors' Reply to Yu et al.: "Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?"

Didier Concordet et al. Clin Pharmacokinet. 2020 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A. Ferran, and Pierre-Louis Toutain have no conflicts of interest that are directly relevant to the content of this reply.

Comment on

References

    1. Yu Y, Maliepaard M. Comment on: “Levothyrox® new and old formulations: are they switchable for millions of patients?”. Clin Pharmacokinet. 2019 doi: 10.1007/s40262-019-00850-5. - DOI - PubMed
    1. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: statistical approaches to establishing bioequivalence. January 2001. https://www.fda.gov/media/70958/download. [Accessed 26 Nov 2019].
    1. Concordet D, Gandia P, Montastruc J-L, Bousquet-Mélou A, Lees P, Ferran AA, et al. Authors’ reply to Coste et al.: Levothyrox® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019;58(7):967–968. doi: 10.1007/s40262-019-00747-3. - DOI - PMC - PubMed
    1. Concordet D, Gandia P, Montastruc J-L, Bousquet-Mélou A, Lees P, Ferran AA, et al. Why were more than 200 subjects required to demonstrate the bioequivalence of a new formulation of levothyroxine with an old one? Clin Pharmacokinet. 2019 doi: 10.1007/s40262-019-00812-x. - DOI - PMC - PubMed
    1. Anonymous. Draft guidance on levothyroxine sodium. Food and Drug Administration; 2018: :p. 2. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformat.... Accessed 4 Oct 2019.

LinkOut - more resources